{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:37:35Z","timestamp":1792517855337,"version":"4.5.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The introduction of CAR (chimeric antigen receptor) T-cell therapy and bispecific antibodies into clinical practice has revolutionized the treatment landscape of relapsed\/refractory multiple myeloma (RRMM). Both modalities have shown impressive clinical efficacy with slightly different but overall manageable toxicity profiles. At present, two B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are approved for standard use in the United States. There are currently 4 commercially approved bispecific antibodies: teclistamab, elranatamab, and linvoseltamab, which target BCMA, as well as talquetamab, which targets the GPRC5D antigen on the surface of plasma cells. In this review, we explore (a) the advantages and challenges of integrating CAR T-cell therapy earlier in the RRMM treatment course; (b) the safety and efficacy of bispecific antibodies and their evolving role in the current RRMM treatment paradigm; (c) practical considerations for both modalities, focusing on patient selection and supportive care strategies; and (d) recommendations for sequencing of T-cell redirecting therapies to maximize long-term outcomes.<\/jats:p>","DOI":"10.1182\/hematology.2025000721","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:33Z","timestamp":1764943713000},"page":"324-333","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma"],"prefix":"10.1182","volume":"2025","author":[{"given":"Danai","family":"Dima","sequence":"first","affiliation":[{"name":"1 University of Washington, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2 H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Morsani College of Medicine, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"1 University of Washington, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2 H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Morsani College of Medicine, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"2 H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Morsani College of Medicine, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"1","key":"2025120616332199500_hem2025000721C1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2025120616332199500_hem2025000721C2","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025120616332199500_hem2025000721C3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"2025120616332199500_hem2025000721C4","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025120616332199500_hem2025000721C5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2025120616332199500_hem2025000721C6","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(24)02346-2","article-title":"Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update","volume-title":"2024 International Myeloma Society Annual Meeting","author":"Mateos","year":"2024"},{"key":"2025120616332199500_hem2025000721C7","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","article-title":"Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient- reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025120616332199500_hem2025000721C8","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina","year":"2025","journal-title":"Lancet Haematol"},{"key":"2025120616332199500_hem2025000721C9","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"0","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025120616332199500_hem2025000721C10","doi-asserted-by":"crossref","unstructured":"Banerjee\n              R\n            \n          , CiceroKI, LeeSS, CowanAJ. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling [Internet]. Front Oncol. 2025;13. Accessed 1April2025. https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2023.1240966\/full.","DOI":"10.3389\/fonc.2023.1240966"},{"issue":"16","key":"2025120616332199500_hem2025000721C11","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2024.42.16_suppl.7504","article-title":"Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis","volume":"42","author":"Costa","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025120616332199500_hem2025000721C12","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1200\/JCO.2025.43.16_suppl.7539","article-title":"Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed\/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses","volume":"43","author":"Sidana","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025120616332199500_hem2025000721C13","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas","year":"2024","journal-title":"Nat Med"},{"issue":"13","key":"2025120616332199500_hem2025000721C14","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma","volume":"43","author":"Hansen","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025120616332199500_hem2025000721C15","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.jtct.2025.01.330","article-title":"Prophylactic dexamethasone rescues unrestrained lymphocyte expansion in anti-BCMA chimeric antigen receptor T cell therapy in multiple myeloma","volume":"31","author":"Turner","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"16","key":"2025120616332199500_hem2025000721C16","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1200\/JCO.2025.43.16_suppl.7522","article-title":"Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (pts) receiving cilta-cel","volume":"43","author":"Lim","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025120616332199500_hem2025000721C17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025120616332199500_hem2025000721C18","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"20","key":"2025120616332199500_hem2025000721C19","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025120616332199500_hem2025000721C20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"2025120616332199500_hem2025000721C21","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"18","key":"2025120616332199500_hem2025000721C22","first-page":"1722","article-title":"Teclistamab in relapsed or refractory multiple myeloma. Reply","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"2025120616332199500_hem2025000721C23","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2025120616332199500_hem2025000721C24","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025120616332199500_hem2025000721C25","article-title":"Long-term survival after elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM): MagnetisMM-3","volume-title":"European Hematology Association","author":"Mohty","year":"2024"},{"issue":"16","key":"2025120616332199500_hem2025000721C26","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025120616332199500_hem2025000721C27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA- targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025120616332199500_hem2025000721C28","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2025120616332199500_hem2025000721C29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","article-title":"Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM","volume":"14","author":"Malard","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025120616332199500_hem2025000721C30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/blood-2024-203409","article-title":"Outcomes of teclistamab (Tec) in patients with relapsed\/refractory multiple myeloma (RRMM) with prior exposure to BCMA-directed therapy (BCMA-DT): a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium","volume":"144","author":"Dima","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025120616332199500_hem2025000721C31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-024-01129-0","article-title":"Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel","volume":"14","author":"Banerjee","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025120616332199500_hem2025000721C32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025120616332199500_hem2025000721C33","doi-asserted-by":"crossref","DOI":"10.1200\/OP-24-00921","article-title":"Impatient for outpatient: operationalizing bispecific antibodies for multiple myeloma in the ambulatory setting","volume":"21","author":"Olivieri","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"2025120616332199500_hem2025000721C34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025120616332199500_hem2025000721C35","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"7","key":"2025120616332199500_hem2025000721C36","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"},{"issue":"1","key":"2025120616332199500_hem2025000721C37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"10","key":"2025120616332199500_hem2025000721C38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2025120616332199500_hem2025000721C39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"Supplement 1","key":"2025120616332199500_hem2025000721C40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood-2024-199374","article-title":"Effects of intravenous immunoglobulin supplementation (IVIG) on infections in recipients of teclistamab therapy for multiple myeloma (MM): a multi-institutional study","volume":"144","author":"Cheruvalath","year":"2024","journal-title":"Blood"},{"issue":"13","key":"2025120616332199500_hem2025000721C41","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/bloodadvances.2024015344","article-title":"Restarting teclistamab and talquetamab after prolonged dose delay may not require re-step-up dosing","volume":"9","author":"Tan","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2025120616332199500_hem2025000721C42","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"10","key":"2025120616332199500_hem2025000721C43","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/03007995.2024.2387183","article-title":"Real-world experience with clinical management of talquetamab in relapsed\/refractory multiple myeloma: a qualitative study of US healthcare providers","volume":"40","author":"Schinke","year":"2024","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2025120616332199500_hem2025000721C44","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"},{"key":"2025120616332199500_hem2025000721C45","article-title":"Talquetamab bridging: paving the way to B-cell maturation antigen (BCMA) CAR-T cell therapy in relapsed\/refractory multiple myeloma (RRMM) [published online 1 August 2025]","author":"Dhakal","journal-title":"Blood"},{"issue":"2","key":"2025120616332199500_hem2025000721C46","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"2025120616332199500_hem2025000721C47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"2025120616332199500_hem2025000721C48","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"2025120616332199500_hem2025000721C49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2024-201288","article-title":"Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"144","author":"Maura","year":"2024","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/324\/2470448\/324dima.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/324\/2470448\/324dima.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:33:31Z","timestamp":1765056811000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/324\/556925\/CAR-T-cell-therapy-and-bispecific-antibodies-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000721","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}